Evidence map›Paper›PMID 35417043›Full record

ArticleMolecular carcinogenesis2022

Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity.

Khoa A Nguyen, Madison J Keith, Stephen B Keysar, Spencer C Hall, Anamol Bimali, Antonio Jimeno, Xiao-Jing Wang, Christian D Young

Open access · greenAbstract read
In one paragraph

Article in Molecular carcinogenesis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Khoa A NguyenDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Madison J KeithDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Stephen B KeysarDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Spencer C HallDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Anamol BimaliDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Antonio JimenoDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Xiao-Jing WangDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Christian D YoungDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0001-9846-488X
University of Colorado Anschutz Medical Campus · USVA Eastern Colorado Health Care System · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.P50CA261605 · NCI · UNIVERSITY OF COLORADO DENVER · PI LUCIA, M. SCOTT · 2021 to 2025
$10.1M
Elucidating Mechanism of Immune Evasion in Head and Neck CancersR01DE027329 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, JING HONG, WANG, XIAO-JING · 2018 to 2022
$2.8M
Mechanisms of Dual Inhibition of TGFbeta/PD-L1 in HNSCCR01DE028420 · NIDCR · UNIVERSITY OF COLORADO DENVER · PI WANG, JING HONG, WANG, XIAO-JING · 2019 to 2023
$2.7M
Identifying oral cancer stem cell properties affected by the microenvironmentR01DE024371 · NIDCR · UNIVERSITY OF COLORADO DENVER · PI JIMENO, ANTONIO, WANG, XIAO-JING · 2014 to 2017
$2.1M
BLR&D Research Career Scientist ApplicationIK6BX005962 · VA · OMAHA VA MEDICAL CENTER · PI WYATT, TODD A · 2022 to 2025
–
Mechanisms of Breaking Indolence in Squamous Cell CarcinomaI01BX003232 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI WANG, XIAO-JING · 2017 to 2025
–
BLRD VA I01 BX003232BLRD VA IK6 BX005962BLRD VA IK6 BX006039NCI NIH HHS P30 CA046934NCI NIH HHS P50 CA261605NIDCR NIH HHS R01 DE024371NIDCR NIH HHS R01 DE027329NIDCR NIH HHS R01 DE028420
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is commonly associated with tobacco and alcohol consumption that induce a "precancerous field," with phosphoinositide 3-kinase (PI3K) signaling being a common driver. However, the preclinical effectiveness of PI3K inhibitors has not necessarily translated to remarkable benefit in HNSCC patients. Thus, we sought to determine how precancerous keratinocytes influence HNSCC proliferation, cancer stem cell (CSC) maintenance, and response to PI3K inhibitors. We used the NOK keratinocyte cell line as a model of preneoplastic keratinocytes because it harbors two frequent genetic events in HNSCC, CDKN2A promoter methylation and TP53 mutation, but does not form tumors. NOK cell coculture or NOK cell-conditioned media promoted HNSCC proliferation, PI3K inhibitor resistance, and CSC phenotypes. SOMAscan-targeted proteomics determined the relative levels of >1300 analytes in the media conditioned by NOK cells and HNSCC cells ± PI3K inhibitor. These results demonstrated that NOK cells release abundant levels of ligands that activate epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor (FGFR), two receptor tyrosine kinases with oncogenic activity. Inhibition of EGFR, but not FGFR, blunted PI3K inhibitor resistance and CSC phenotypes induced by NOK cells. Our results demonstrate that precancerous keratinocytes can directly support neighboring HNSCC by activating EGFR. Importantly, PI3K inhibitor sensitivity was not necessarily a cancer cell-intrinsic property, and the tumor microenvironment impacts therapeutic response and supports CSCs. Additionally, combined inhibition of EGFR with PI3K inhibitor diminished EGFR activation induced by PI3K inhibitor and potently inhibited cancer cell proliferation and CSC maintenance.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsPrecancerous ConditionsCell Line, TumorErbB ReceptorsHumansKeratinocytesNeoplastic Stem CellsPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsReceptors, Fibroblast Growth FactorSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentEGFR protein, humanErbB ReceptorsPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsReceptors, Fibroblast Growth Factorcancer stem cellEGFRHNSCCPI3Kresistancesquamous cell carcinoma

Identifiers

PMID35417043
PMCPMC9233118
OpenAlexW4223468151

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.